Federal Register / Vol. 70, No. 170 / Friday, September 2, 2005 / Notices 52405 

inhibitors in vitro and can be used to 

test drug candidates for their 

effectiveness against common drug 

resistant mutants of HIV–1 RT. Please 

contact Dr. Hughes directly 

(hughes@ncifcrf.gov) if you want 

additional information about RT 

expression plasmids that are not listed 

below. 

Vector Description Reference No. 

Wild-type HIV–1 RT ................................................................. full length, wild type ................................................................. E–034–1991/0 

L100I ........................................................................................ NNRTI resistant ....................................................................... E–034–1991/1 

K103N ...................................................................................... NNRTI resistant ....................................................................... E–034–1991/1 

V106A ...................................................................................... NNRTI resistant ....................................................................... E–034–1991/1 

V108I ........................................................................................ .................................................................................................. ..............................

E138K ...................................................................................... NNRTI resistant ....................................................................... E–034–1991/1 

Y181I ........................................................................................ .................................................................................................. ..............................

Y181C ...................................................................................... NNRTI resistant ....................................................................... E–034–1991/1 

Y188L ....................................................................................... .................................................................................................. ..............................

Y188H ...................................................................................... NNRTI resistant ....................................................................... E–034–1991/1 

G190A ...................................................................................... .................................................................................................. ..............................

G190S ...................................................................................... .................................................................................................. ..............................

P236L ....................................................................................... NNRTI resistant ....................................................................... E–034–1991/1 

RTs that carry some combinations of NNRTI mutations, e.g., K103N+Y181I, are also available. 

K65R ........................................................................................ NRTI resistant ......................................................................... E–034–1991/2 

T69G ........................................................................................ .................................................................................................. ..............................

L74V ......................................................................................... NRTI resistant ......................................................................... E–034–1991/1 

M184I ....................................................................................... Lamivudine (3TC) resistant ..................................................... ..............................

M184V ...................................................................................... Lamivudine (3TC) resistant ..................................................... E–034–1991/1 

AZT–R (5 mutations) ............................................................... AZT resistant ........................................................................... E–034–1991/1 

D67 complex ............................................................................ Multi-NRTI resistant ................................................................. E–034–1991/4 

Q151M ..................................................................................... Multi-NRTI resistant ................................................................. E–034–1991/4 

Q151M Complex ...................................................................... Multi-NRTI resistant ................................................................. E–034–1991/4 

SSGR/T215Y ........................................................................... Multi-NRTI resistant ................................................................. E–034–1991/4 

SSSR/T215Y ............................................................................ Multi-NRTI resistant ................................................................. E–034–1991/4 

Dated: August 20, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 05–17517 Filed 9–1–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center on Minority Health and 

Health Disparities; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given by the National 

Advisory Council on Minority Health 

and Health Disparities. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Minority Health and Health 

Disparities. 

Date: September 20, 2005. 

Closed: 8:30 a.m. to 10 a.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Suite 800, Bethesda, MD 20892. 

Open: 10:30 a.m. to 5:30 p.m. 

Agenda: The agenda will include Opening 

Remarks, Administrative Matters, Director’s 

Report, NCMHD, IC Health Disparities 

Research Report, NCMHD Program 

Highlights, and other business of the Council. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Suite 800, Bethesda, MD 20892. 

Contact Person: Donna Brooks, Asst. 

Director for Administration, National Center 

on Minority Health and Health Disparities, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 800, Bethesda, MD 

20892, 301–435–2135, 

brooksd@ncmhd.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Dated: August 25, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–17514 Filed 9–1–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Eye Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,